Exchange: NASDAQ·Updated 02:21 PM EDT
SYRE logo

SYRE Spyre Therapeutics Inc

$86.70
$0.35
(0.40%)
Today
Reported EarningsAug 4
Mkt Cap$7.68B
Vol519,454.00

About SYRE

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
42

Bearish Sentiment

How do you feel about SYRE?

Advertisement|Remove ads.